|
Toggle Summary
November 7, 2018
|
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
WALTHAM, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London
|
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
|
|
Toggle Summary
November 5, 2018
|
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today
|
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
|
|
Toggle Summary
October 29, 2018
|
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
Management to host conference call WALTHAM, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
|
|
Toggle Summary
August 22, 2018
|
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
WALTHAM, Mass. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced findings from a recent pre-clinical study that provide
|
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
|
|
Toggle Summary
August 2, 2018
|
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
Five ongoing late-stage trials on track for data readouts in 2019 WALTHAM, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today
|
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
|
|
Toggle Summary
July 26, 2018
|
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
Management to host conference call WALTHAM, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
|
|
Toggle Summary
July 25, 2018
|
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
WALTHAM, Mass. , July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Devin W.
|
Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
|
|
Toggle Summary
July 17, 2018
|
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
WALTHAM, Mass. , July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors
|
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
|
|
Toggle Summary
May 30, 2018
|
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
WALTHAM, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2018
|
Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
|
|
Toggle Summary
May 17, 2018
|
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass. , May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published
|
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
|
